M Kanai

Summary

Affiliation: Kyoto University
Country: Japan

Publications

  1. ncbi Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, Japan
    Cancer Chemother Pharmacol 69:1181-8. 2012
  2. ncbi Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer
    M Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogin Kawahara cho, Sakyo ku, Kyoto, Japan
    Br J Cancer 105:1693-6. 2011
  3. ncbi A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia
    M Kanai
    Outpatient Oncology Unit, Graduate School of Medicine, Kyoto University Hospital, Sakyo ku, Kyoto, Japan
    Ann Oncol 20:1397-401. 2009
  4. ncbi A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho Sakyo ku, Kyoto, Japan
    Cancer Chemother Pharmacol 67:1429-34. 2011
  5. ncbi A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 68:157-64. 2011
  6. ncbi Pure gastric yolk sac tumor that was diagnosed after curative resection: case report and review of literature
    Masashi Kanai
    Digestive Disease Center, Kyoto Katsura Hospital, 17 Yamada Hirao cho, Nishikyo ku, Kyoto, 615 8256, Japan
    Int J Gastrointest Cancer 35:77-81. 2005
  7. ncbi Efficacy of argon plasma coagulation in nonvariceal upper gastrointestinal bleeding
    M Kanai
    Center for Gastrointestinal Endoscopy, Kyoto Katsura Hospital, Kyoto, Japan
    Endoscopy 36:1085-8. 2004
  8. ncbi Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 69:65-70. 2012
  9. ncbi Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Epidemiol 34:189-93. 2010
  10. ncbi A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis
    C Zaima
    Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto, Japan
    Jpn J Clin Oncol 41:803-6. 2011

Collaborators

Detail Information

Publications22

  1. ncbi Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, Japan
    Cancer Chemother Pharmacol 69:1181-8. 2012
    ....
  2. ncbi Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer
    M Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogin Kawahara cho, Sakyo ku, Kyoto, Japan
    Br J Cancer 105:1693-6. 2011
    ..A blood pressure drop after bevacizumab administration and its clinical significance have not been previously reported...
  3. ncbi A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia
    M Kanai
    Outpatient Oncology Unit, Graduate School of Medicine, Kyoto University Hospital, Sakyo ku, Kyoto, Japan
    Ann Oncol 20:1397-401. 2009
    ..Smoking may affect the efficacy of chemotherapy and the incidence of adverse events. We investigated the correlation between smoking history and gemcitabine-induced neutropenia...
  4. ncbi A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho Sakyo ku, Kyoto, Japan
    Cancer Chemother Pharmacol 67:1429-34. 2011
    ..We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination chemotherapy for the treatment of patients with advanced biliary tract cancer...
  5. ncbi A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 68:157-64. 2011
    ..We evaluated the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy...
  6. ncbi Pure gastric yolk sac tumor that was diagnosed after curative resection: case report and review of literature
    Masashi Kanai
    Digestive Disease Center, Kyoto Katsura Hospital, 17 Yamada Hirao cho, Nishikyo ku, Kyoto, 615 8256, Japan
    Int J Gastrointest Cancer 35:77-81. 2005
    ..Five out of six cases are accompanied by components of adenocarcinoma, and our present case is the second report of pure gastric yolk sac tumor to the best of our knowledge...
  7. ncbi Efficacy of argon plasma coagulation in nonvariceal upper gastrointestinal bleeding
    M Kanai
    Center for Gastrointestinal Endoscopy, Kyoto Katsura Hospital, Kyoto, Japan
    Endoscopy 36:1085-8. 2004
    ..The aim of this study was to evaluate the efficacy of APC in various types of upper gastrointestinal bleeding...
  8. ncbi Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Chemother Pharmacol 69:65-70. 2012
    ..However, poor bioavailability has limited its efficacy in clinical trials, and plasma curcumin levels remain low despite patients taking gram doses of curcumin...
  9. ncbi Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto 606 8507, Japan
    Cancer Epidemiol 34:189-93. 2010
    ....
  10. ncbi A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis
    C Zaima
    Kyoto University Hospital, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto, Japan
    Jpn J Clin Oncol 41:803-6. 2011
    ..Any resulting digital ischemia might be refractory to treatment and worsen progressively, even if chemotherapy is withdrawn in the early stages of digital ischemia...
  11. ncbi Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX
    Yukiko Mori
    Department of Translational Clinical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Oncology 79:136-43. 2010
    ..However, the effect of an oxaliplatin-free interval on HSR occurrence remains poorly understood...
  12. ncbi Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy
    Toshiyuki Kitano
    Department of Translational Clinical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Int J Hematol 86:37-41. 2007
    ..Better recognition and management of cancer-related anemia are required in Japan. To this end, randomized controlled trials evaluating the effects of erythropoietic agents on patients' survival and quality of life are necessary...
  13. ncbi Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study
    Shigemi Matsumoto
    Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, Japan
    Chemotherapy 54:395-403. 2008
    ..The aim of this observational study was to assess the safety and efficacy of a modified version of the FOLFOX6 regimen (mFOLFOX6) when administered using the 'stop-and-go' strategy...
  14. ncbi Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer
    Kazuhiro Yanagihara
    Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, Japan
    Cancer Chemother Pharmacol 66:913-8. 2010
    ..The purpose of the present phase II study was to evaluate both the efficacy and toxicity of the combination of S-1 and docetaxel in previously treated patients with locally advanced or metastatic non-small cell lung cancer...
  15. ncbi Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer
    Masashi Kanai
    Outpatient Oncology Unit, Kyoto University Hospital, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto, 606 8507, Japan
    Int J Clin Oncol 12:224-7. 2007
    ..The aim of this study was to evaluate the efficacy and safety of combination therapy with docetaxel and nedaplatin in advanced esophageal cancer as a second-line regimen in an outpatient setting...
  16. ncbi UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
    Masahide Onoue
    Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, 54 Shogoin Kawahara cho, Sakyo ku, Kyoto, 606 8507, Japan
    Int J Clin Oncol 14:136-42. 2009
    ..In the present study, we evaluated the association of genetic polymorphisms of UGT1A1 and SLCO1B1 with irinotecanrelated neutropenia in Japanese cancer patients...
  17. ncbi STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells
    Naoki Kanda
    Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Shogoin Kawara cho 54, Sakyo ku, Kyoto 606 8507, Japan
    Oncogene 23:4921-9. 2004
    ..5%) human gastric cancer specimens. These findings suggest that constitutively activated STAT3 signaling supports gastric cancer cell survival in association with survivin expression.2004..
  18. ncbi Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway
    Masashi Kanai
    Division of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Japan
    Oncogene 22:548-54. 2003
    ....
  19. ncbi Prohormone convertase furin has a role in gastric cancer cell proliferation with parathyroid hormone-related peptide in a reciprocal manner
    Toshio Nakajima
    Division of Gastroenterology and Hepatology, Kyoto University, Graduate School of Medicine, Kyoto, Japan
    Dig Dis Sci 47:2729-37. 2002
    ..These results suggest a link between PTHrP and furin in the regulation of gastric cancer cell growth. Furin might be involved not only in the production of the mature form of PTHrP, but also in promoting growth in gastric cancer cells...
  20. ncbi Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression
    Masashi Kanai
    Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:6395-402. 2006
    ..CONCLUSIONS: Our data suggests that disruption of KLF4-mediated negative regulation contributes to the molecular events of Sp1 overexpression and to the development and progression of human gastric cancer...
  21. ncbi Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression
    Daoyan Wei
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:2746-54. 2005
    ..Collectively, our data provide first clinical and casual evidence and potential mechanism that the alteration of KLF4 expression plays a critical role in gastric cancer development and progression...
  22. ncbi [A case of effective weekly paclitaxel administration for primary lesion of schirrous gastric cancer]
    Mitsunari Ogasawara
    Dept. of Gastroenterology, Kyoto Katsura Hospital
    Gan To Kagaku Ryoho 31:91-3. 2004
    ..A weekly paclitaxel regimen appears to be one of the promising treatment for schirrous gastric cancer...